Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Ursula A Matulonis
  • Lydia Walder
  • Trine J Nøttrup
  • Paul Bessette
  • Sven Mahner
  • Marta Gil-Martin
  • Elsa Kalbacher
  • Jonathan A Ledermann
  • Robert M Wenham
  • Kathrine Woie
  • Susie Lau
  • Frederik Marmé
  • Antonio Casado Herraez
  • Anne-Claire Hardy-Bessard
  • Susana Banerjee
  • Gabriel Lindahl
  • Benedict Benigno
  • Joseph Buscema
  • Karin Travers
  • Holly Guy
  • Mansoor R Mirza
Vis graf over relationer

PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer.

PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post-random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs.

RESULTS: In the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons.

CONCLUSION: Patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control.

OriginalsprogEngelsk
TidsskriftJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Vol/bind37
Udgave nummer34
Sider (fra-til)3183-3191
Antal sider9
ISSN0732-183X
DOI
StatusUdgivet - 1 dec. 2019

ID: 59076433